Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:DYN News 9 December 2025 - 4 January 2026

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics (DYN), SLM Corp (SLM), Kontoor Brands (KTB) and Waystar Holding (WAY). Investing.com+1 According to real‑time data from StockScan, the 10 biggest U.S. stock losers today by percentage move (among actively traded listed shares) are: StockScan Below is a breakdown of what’s driving today’s biggest losers, plus how they fit into the
10 December 2025
···········
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

The US stock market spent most of Tuesday, December 9, 2025 trading quietly ahead of this week’s Federal Reserve decision — but beneath the calm index surface, several individual stocks suffered brutal double‑digit losses. As of around 3:44 p.m. ET, live data from Public.com showed TuHURA Biosciences (HURA), Phreesia (PHR), Euda Health (EUDA), SLM Corp (SLM), Virgin Galactic (SPCE), Gogo (GOGO), Compass Minerals (CMP), Workhorse Group (WKHS), 3D Systems (DDD) and Dyne Therapeutics (DYN) among the steepest percentage decliners across US‑listed stocks. Public Below is a detailed look at what drove today’s biggest losers — and what analysts and companies
9 December 2025
··········
Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

December 9, 2025 — Dyne Therapeutics, Inc. (NASDAQ: DYN) shares were volatile on Tuesday, giving back part of a recent rally even as Wall Street responded positively to new clinical data and raised price targets on the neuromuscular‑disease biotech. In early afternoon U.S. trading, Dyne stock was changing hands around $19.15, down roughly 14% on the day after opening near $21.41 and moving in a range between about $19 and $22. The pullback follows a sharp advance on Monday, when the shares jumped high‑single‑digits after the company released detailed positive Phase 1/2 results from its DELIVER trial in Duchenne muscular
9 December 2025
··

Stock Market Today

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

8 February 2026
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Longsys disclosed new guarantees for a 100 million yuan Hong Kong loan and a $9 million Brazil credit line, bringing its total approved guarantee quota to 11 billion yuan and outstanding guarantees to 5.81 billion yuan. The company said all guarantees are for consolidated subsidiaries and within approved limits. Shares closed at 288 yuan Friday, down 1.6%. China inflation and credit data are due this week.
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop